Literature DB >> 26644053

Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial.

Ayse N Tufan1, Fatih Tufan2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26644053     DOI: 10.1212/01.wnl.0000475736.75775.25

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  5 in total

Review 1.  The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-α, TGF-β and IFN-γ.

Authors:  Cong Zheng; Xin-Wen Zhou; Jian-Zhi Wang
Journal:  Transl Neurodegener       Date:  2016-04-05       Impact factor: 8.014

Review 2.  Neuroinflammation in Alzheimer's Disease: Current Progress in Molecular Signaling and Therapeutics.

Authors:  Sujata Thakur; Rishika Dhapola; Phulen Sarma; Bikash Medhi; Dibbanti HariKrishna Reddy
Journal:  Inflammation       Date:  2022-08-20       Impact factor: 4.657

Review 3.  Cytokine signaling convergence regulates the microglial state transition in Alzheimer's disease.

Authors:  Shun-Fat Lau; Amy K Y Fu; Nancy Y Ip
Journal:  Cell Mol Life Sci       Date:  2021-04-13       Impact factor: 9.261

4.  No increased risk of Alzheimer's disease among people with immune-mediated inflammatory diseases: findings from a longitudinal cohort study of U.S. older adults.

Authors:  Michael J Booth; Lindsay C Kobayashi; Mary R Janevic; Daniel Clauw; John D Piette
Journal:  BMC Rheumatol       Date:  2021-11-12

Review 5.  Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach.

Authors:  Xavier Morató; Vanesa Pytel; Sara Jofresa; Agustín Ruiz; Mercè Boada
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.